Cell No. : Cell Name
RCB1200 : MMAc·SF
update : 2022/08/24
|
| Comment | Serum-free medium-adapted MMAc cells. For SF culture, + insulin, hEGF, hydrocortisone, bovine pituit |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Katayama, Hiroshi
|
| Originator |
Katayama, Hiroshi
|
| Year of deposit |
1996
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Female
|
| Age at sampling |
39 years
|
| Tissue |
melanoma, ascites meta
|
| Metastatic ability |
Yes
|
| Metastatic tissue |
liver, lymph node et
|
| Classification |
cancer
|
| Year of origin |
1995
|
|
Lifespan |
infinite
|
| Morphology |
other
|
| Cellosaurus(Expasy) |
CVCL_1420
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
HuMedia-KG2
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin, added HuMedia-KG2 + 10%FBS, washed twice with HuMedia-KG2
|
Culture information
|
Passage ratio |
|
1 : 3-4 split
|
| SC frequency |
|
Subculture : once/10 days, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
HuMedia : 2 x FM1 = 1 : 1
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
69-80(16) : /72(1),72(2),74(1),75(2),76(3),77(3)/
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
0
|
| User's Publication |
4
|
| User's Publication |
|
20812
Comandante-Lou N, Baumann DG, Fallahi-Sichani M.
AP-1 transcription factor network explains diverse patterns of cellular plasticity in melanoma cells.
Cell Rep
2022
40(5)
PubMed ID: 35926467
DOI: 10.1016/j.celrep.2022.111147
|
|
18107
Comandante-Lou N, Khaliq M, Venkat D, Manikkam M, Fallahi-Sichani M.
Phenotype-based probabilistic analysis of heterogeneous responses to cancer drugs and their combination efficacy
PLoS Comput Biol
2020
16(2):e1007688
PubMed ID: 32084135
DOI: 10.1371/journal.pcbi.1007688
|
|
13309
Gerosa L, Chidley C, Fröhlich F, Sanchez G, Lim SK, Muhlich J, Chen JY, Vallabhaneni S, Baker GJ, Schapiro D, Atanasova MI, Chylek LA, Shi T, Yi L, Nicora CD, Claas A, Ng TSC, Kohler RH, Lauffenburger DA, Weissleder R, Miller MA, Qian WJ, Wiley HS, Sorger PK.
Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells.
Cell Syst
2020
PubMed ID: 33113355
DOI: 10.1016/j.cels.2020.10.002
|
|
14264
Ward GA, Lewis EJ, Ahn JS, Johnson CN, Lyons JF, Martins V, Munck JM, Rich SJ, Smyth T, Thompson NT, Williams PA, Wilsher NE, Wallis NG, Chessari G.
ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth
Mol Cancer Ther
2018
17(7):1381-1391
PubMed ID: 29695633
DOI: 10.1158/1535-7163.MCT-17-0848
|
Back
Top
CELL BANK Website